A landmark study by Halip et al. in Nature Reviews Drug Discovery provides a comprehensive, quantitative map of the global drug target landscape. Drawing from DrugCentral data and regulatory review archives, the authors analyze the molecular mechanism-of-action (MoA) targets through which approved drugs mediate their therapeutic effects. By standardizing target definitions and collapsing large protein complexes to eliminate counting bias, this benchmark exposes the structural evolution, modality preferences, and regulatory dynamics of modern pharmacology. Below is a condensed, data-first summary of the core findings.
1. Global Baseline and Target Taxonomy
The global pharmacopoeia encompasses 1,702 approved drugs modulating 686 distinct MoA biomolecular targets. Modality distribution is dominated by synthetic small molecules (79%, n=1,339), followed by biologics (19%, n=330) and other modalities such as radioligands and inorganic salts (2%, n=33).
Human biomolecules account for 90% (n=610) of all MoA targets, while pathogen biomolecules represent the remaining 10% (n=76). Antimicrobial pathogen targets comprise 32 bacterial, 27 viral, 13 parasitic, and 6 fungal targets, illustrating how conserved enzymatic targets like dihydrofolate reductase (DHFR) can be therapeutically exploited across multiple species.
2. Proteomic Architecture and Modality Specialization
Among the 610 human targets, four primary protein families account for 78% (n=475) of the total target landscape:
- Enzymes: 34% (n=209).
- G-Protein-Coupled Receptors (GPCRs): 17% (n=101).
- Ion Channels: 15% (n=92).
- Catalytic Receptors: 12% (n=73).
Smaller protein classes include transporters (4%, n=23), nuclear hormone receptors (3%, n=19), endogenous peptides (7%, n=42), and miscellaneous proteins (8%, n=51).
Small molecules and biologics display sharp, complementary target preferences dictated by subcellular access limitations:
- Small Molecules: Predominantly target intracellular and membrane-embedded proteins, including enzymes (n=191; 91% of enzyme targets), ion channels (n=90; 98% of ion channel targets), and GPCRs (n=74). Although GPCRs rank fourth in target count, they are modulated by the largest number of individual small molecules (n=358 drugs). Furthermore, nuclear hormone receptors (n=19) and membrane transporters (n=21) are almost exclusively targeted by small molecules.
- Biologics: Focus on extracellular and cell-surface targets, dominating catalytic receptors (n=49) and endogenous peptides (n=40 targets modulated by 64 biologics) to intercept soluble signaling mediators like cytokines and growth factors.
3. Post-2000 Target Dynamics and the Kinase Expansion
The completion of the Human Genome Project draft in 2000 marked a turning point in drug discovery. Post-2000 approvals introduced 312 novel MoA targets, representing an 84% expansion over the 375 targets established pre-2000.
While pre-2000 target discovery favored small molecules over biologics by a 6:1 ratio (330 vs. 54 targets), the post-2000 target introduction ratio shifted dramatically to 1.35:1 (188 vs. 140 targets). By 2023, annual approvals for biologics reached parity with small molecules.
Post-2000 target expansion was heavily driven by a 7.2-fold increase in endogenous peptide targets and a 2.0-fold increase in catalytic receptors. In contrast, traditional families like ion channels and nuclear receptors experienced near-saturation, expanding marginally from 83 to 91 targets and 18 to 19 targets, respectively. A major engine of post-2000 innovation was the protein kinase family: 136 approved kinase inhibitors (78% small molecules) now target 67 distinct human kinases, predominantly in oncology.
4. Binding Potency, Timelines, and Regulatory Geography
Structure-based drug design (SBDD) and high-throughput screening have significantly enhanced chemical quality:
- Binding Potency: The mean in vitro binding potency (log10M) of small-molecule drugs increased from 7.4 pre-2000 to 8.2 post-2000, shifting average binding affinity into the sub-10 nM range. Kinase inhibitors demonstrate an exceptional mean potency of 8.4.
- Development Timelines: The median time from first public disclosure (CAS registration) to market authorization is 6 years for biologics compared to 11 years for small molecules. Monoclonal antibodies and RNA therapeutics achieve the fastest approvals (5–6 years), whereas first-in-class drugs targeting novel mechanisms average 10 years regardless of modality.
- Regulatory Leadership: Over 80% (n=616) of post-2000 novel drugs received their first market approval from the US FDA, which validated 78% of all post-2000 novel MoA targets.
5. Next-Generation Frontiers: Oligonucleotides and CGTs
RNA therapeutics have established themselves as a core therapeutic modality, with 22 approved oligonucleotide drugs, including 7 siRNAs and multiple antisense oligonucleotides (ASOs) that induce sequence-specific mRNA degradation or splice modulation.
Finally, cell and gene therapies (CGTs) address 14 exclusive targets (e.g., BCL11A, HBB, RPE65, F8, OTOF, ABCD1, ARSA, COL7A1) that remain inaccessible to conventional modalities. These therapies overcome three critical barriers:
- Monogenic Replacement: Delivering functional copies of deficient intracellular enzymes or structural proteins.
- Genomic Editing: Performing precise genomic disruption (e.g., CRISPR-Cas9 editing of BCL11A for sickle cell disease).
- Anatomical Barriers: Targeting privileged tissue compartments like the inner ear, central nervous system, or blood-retina barrier.
